The Broad Institute, Inc.

The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, is a non-profit biomedical and genomic research organization operating as a prime recipient of federal grants and a prime contractor for genomic services and data analysis, with roughly $1.88 billion in combined potential value across 778 recent federal awards spanning contracts, IDVs, and grants. The Institute does not compete under set-asides and receives funding across 45 federal agencies, with concentration among National Institutes of Health components.

The Broad Institute's federal capability portfolio centers on large-scale genomic sequencing, analysis, and data management infrastructure supporting precision medicine and biomedical research. Representative prime work includes a $500 million single-award indefinite delivery contract with the National Heart, Lung, and Blood Institute (NHLBI) for the Trans-Omics for Precision Medicine (TOPMed) initiative, under which the Institute has issued multiple task orders including a $23.4 million delivery order for continued TOPMed Centralized Omics Resource (CORE) support awarded September 2025; a $61.5 million delivery order with the National Institute on Drug Abuse for Task Areas Two through Six of the NIH BRAIN Initiative Cell Atlas Network (BICAN) Sequencing Core supporting large-scale sequencing operations, awarded May 2023; and a $6.7 million project grant from the National Human Genome Research Institute (NHGRI) awarded September 2025 to advance rare disease discovery through the SEQR genomic analysis platform, integrating single-cell and single-nucleus data with long-read sequencing and incorporating variant-level matching across federated rare disease databases.

Customer concentration is pronounced. NHLBI leads by potential value at $1.3 billion across 82 awards (69% of combined potential value); the National Cancer Institute follows at $255.5 million across 113 awards; the National Institute of Mental Health accounts for $149 million across 73 awards. Together, these three agencies represent approximately 97% of combined potential value. The Institute serves 45 distinct federal agencies, but the top five funders account for 52% of recent awards, signaling deep engagement with core NIH institutes rather than a broad-based federal customer base.

The Broad Institute holds positions on four major parent vehicles: the TOPMed CORE contract ($75.7 million across six task orders), the BICAN Sequencing Core ($61.5 million across two task orders), a broad indefinite delivery contract ($51.9 million across three task orders), and the NCI Genomic Characterization Centers ($26.1 million across three task orders). These vehicles anchor the Institute's role as a specialized genomics and precision medicine research infrastructure provider to the NIH ecosystem.

Activity has grown year over year, with 29 awards in 2026 (partial year), 99 in 2025, 120 in 2024, 62 in 2023, and 72 in 2022. Ninety-two awards (combined potential value $159.8 million) reach ultimate completion within the next 24 months and face recompete. The Institute operates as a prime on 62% of recent awards and as a subcontractor on 38%, indicating a primary delivery and infrastructure role with selective use of sub-awards. SCI-reported data (federal service contracts above $150,000, FY2022–FY2024) show $52.1 million in invoiced revenue across prime contracts with 13.9–14.2 FTEs per fiscal year; median government-paid hourly rates run around $1,074/hr, with senior scientific and bioinformatics labor priced through $4,121/hr, reflecting the high-expertise nature of genomic and computational biology work.

The Institute's grant footprint is substantial and diversified across NIH institutes and non-NIH agencies. Representative recent federal grant recipients include awards from NIAID for HIV vaccine antibody development ($165,269), carbapenem-resistant Klebsiella pneumoniae genomic determinants ($480,650), and antimicrobial development based on induced proximity principles ($481,250); NCI awards for cancer immunotherapy engineering ($443,564 for engineered skin bacteria), spatial genomics for tumor analysis ($795,544), and SLFN12 RNase activation mechanisms ($154,400); NINDS awards for prion disease treatment ($481,250) and engineered AAV capsid development ($404,282); NIDDK awards for diabetes genomic risk assessment ($882,180); and DARPA's COASTERCHASE Program ($4.42 million cooperative agreement). Grant sub-awards flow to Duke University, Northwestern University, Jackson Laboratory, Stanford University, University of Washington, and others, establishing the Broad as a hub within a broader research consortium ecosystem.

The Institute operates as a tax-exempt non-profit with one named subsidiary, Broad Clinical Laboratories, LLC, also a non-profit organization. The Broad's federal posture is full-and-open competition on scientific merit rather than set-aside eligibility; federal customers select the Institute for specialized genomic infrastructure, large-scale sequencing platforms, computational biology expertise, and data integration capabilities that anchor precision medicine research across disease domains. With no significant recompete cliff beyond the normal 24-month window and sustained growth in annual award count, the Institute maintains a stable market position as a critical infrastructure provider to the NIH research enterprise.